Rakesh Jain - Tekla Life Independent Trustee
| HQL Stock | USD 14.26 0.13 0.92% |
Executive
Dr. Rakesh K. Jain, Ph.D. is Independent Trustee of HQ Life Sciences Investors. Dr. Jain is the Andrew Werk Cook Professor of Tumor Biology in the Department of Radiation Oncology at Harvard Medical School and the Director of the Edwin L. Steele Laboratory of Tumor Biology at Massachusetts General Hospital, providing each Fund with a valuable perspective on emerging life sciences technologies. Dr. Jain cofounded XTuit Pharmaceuticals, Inc. in 2011, where he also serves as a board member. He serves on the Governance and Nominating Committee of each Fund. Prior to joining Harvard, he was professor of chemical engineering at Columbia University and Carnegie Mellon University. Dr. Jain is regarded as a pioneer in the fields of tumor biology, drug delivery, in vivo imaging and bioengineering. Dr. Jain has authored more than 600 publications. He serves on advisory panels to government, industry and academia, and has served or continues to serve on editorial advisory boards of twenty journals, including Journal of Clinical Oncology and Nature Reviews Clinical Oncology. He has received more than 70 major awards and lectureships, including a Guggenheim Fellowship, the Humboldt Senior Scientist Award, the National Cancer Institute Research Career Development Award and Outstanding Investigator Grant, the Academic Scientist of the Year Award from the Pharmaceutical Achievements Awards, the Distinguished Service Award from Nature Biotechnology and the Innovator Award from the DoD Breast Cancer Program. He is a member of all three branches of US National Academies the Institute of Medicine, the National Academy of Engineering and the National Academy of Sciences and is a member of the American Academy of Arts and Sciences. since 2007.
| Age | 69 |
| Tenure | 17 years |
| Address | 1900 Market Street, Philadelphia, PA, United States, 19103 |
| Phone | 215 405 5700 |
| Web | https://www.teklacap.com/hql.html |
Tekla Life Management Efficiency
The value of Return On Tangible Assets is estimated to slide to 0.04. The value of Return On Capital Employed is expected to slide to -0.02. At this time, Tekla Life's Total Current Assets are quite stable compared to the past year. Asset Turnover is expected to rise to 0.06 this year, although the value of Total Assets will most likely fall to about 335.6 M. Tekla Life's management efficiency ratios could be used to measure how well Tekla Life manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Carole Stone | Nuveen Preferred and | 74 | |
| Frank Fabozzi | Blackrock Muniyield | 73 | |
| William Reardon | Tekla World Healthcare | 74 | |
| Linda Puchalski | Flaherty and Crumrine | 63 | |
| Francis Knox | John Hancock Financial | 73 | |
| Helen Peters | Eaton Vance Tax | 73 | |
| Lauren CFA | Royce Value Closed | N/A | |
| Peter Hoglund | Royce Value Closed | 54 | |
| Cynthia Egan | Blackrock Muniyield | 66 | |
| Kristi Maher | First Trust Intermediate | 54 | |
| James Kirchner | Eaton Vance Tax | 54 | |
| Christopher Flynn | Royce Value Closed | N/A | |
| James Boyle | John Hancock Financial | 61 | |
| Gregory Russo | John Hancock Financial | 71 | |
| Thomas Faust | Eaton Vance Tax | 63 | |
| Thomas Faust | Eaton Vance Tax | 63 | |
| William Reardon | Tekla Healthcare Investors | 74 | |
| Laura Woodward | Tekla Healthcare Opportunities | 51 | |
| Salvatore Schiavone | John Hancock Financial | 55 | |
| David Lamb | Nuveen Preferred and | 57 | |
| Henry Gabbay | Blackrock Muniyield | 72 | |
Management Performance
| Return On Equity | 0.0128 | |||
| Return On Asset | -0.0032 |
Tekla Life Sciences Leadership Team
Elected by the shareholders, the Tekla Life's board of directors comprises two types of representatives: Tekla Life inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Tekla. The board's role is to monitor Tekla Life's management team and ensure that shareholders' interests are well served. Tekla Life's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Tekla Life's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Thomas Kent, Independent Trustee | ||
| William Reardon, Independent Trustee | ||
| Elizabeth Nabel, Independent Trustee | ||
| Oleg Pohotsky, Independent Chairman of the Board of Trustees | ||
| Laura Woodward, Chief Compliance Officer, Treasurer, Secretary | ||
| Dr MS, President Officer | ||
| Peter Branner, Chief Officer | ||
| Lucinda Stebbins, Independent Trustee | ||
| Jeffrey Bailey, Independent Trustee | ||
| Daniel Omstead, Principal Executive Officer and President Trustee and Member of Valuation Committee | ||
| Rakesh Jain, Independent Trustee |
Tekla Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Tekla Life a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0128 | |||
| Return On Asset | -0.0032 | |||
| Profit Margin | 1.56 % | |||
| Operating Margin | (0.32) % | |||
| Current Valuation | 370.8 M | |||
| Shares Outstanding | 27.35 M | |||
| Shares Owned By Insiders | 0.01 % | |||
| Shares Owned By Institutions | 35.35 % | |||
| Number Of Shares Shorted | 74.12 K | |||
| Price To Earning | 2.84 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Tekla Life Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in producer price index. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Is Asset Management & Custody Banks space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tekla Life. If investors know Tekla will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tekla Life listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.425 | Dividend Share 1.3 | Earnings Share 1.34 | Revenue Per Share 0.134 | Quarterly Revenue Growth 0.07 |
The market value of Tekla Life Sciences is measured differently than its book value, which is the value of Tekla that is recorded on the company's balance sheet. Investors also form their own opinion of Tekla Life's value that differs from its market value or its book value, called intrinsic value, which is Tekla Life's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tekla Life's market value can be influenced by many factors that don't directly affect Tekla Life's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tekla Life's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tekla Life is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tekla Life's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.